Loading…
Predictors of HPV incidence and clearance in a cohort of Brazilian HIV-infected women
Persistent infection with high-risk human papillomavirus (HR-HPV) is necessary for the development of precursor lesions and cervical cancer. HPV infection among women living with HIV/AIDS (WLHA) occurs more frequently, presents a higher rate of persistent infections and an earlier progression to can...
Saved in:
Published in: | PloS one 2017-10, Vol.12 (10), p.e0185423-e0185423 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c692t-cff31644605b333b75e297bb682fa53161be5b2b3946ced2af25ecb404e9e8573 |
---|---|
cites | cdi_FETCH-LOGICAL-c692t-cff31644605b333b75e297bb682fa53161be5b2b3946ced2af25ecb404e9e8573 |
container_end_page | e0185423 |
container_issue | 10 |
container_start_page | e0185423 |
container_title | PloS one |
container_volume | 12 |
creator | Travassos, Ana Gabriela Netto, Eduardo Xavier-Souza, Eveline Nóbrega, Isabella Adami, Karina Timbó, Maiara Abbehusen, Karen Fernandes, Sheyla Duran, Camila Haguihara, Tatiana Ferreira, Fábio Brites, Carlos |
description | Persistent infection with high-risk human papillomavirus (HR-HPV) is necessary for the development of precursor lesions and cervical cancer. HPV infection among women living with HIV/AIDS (WLHA) occurs more frequently, presents a higher rate of persistent infections and an earlier progression to cancer. We aimed to evaluate HR-HPV prevalence, incidence and clearance, and its association with HIV viral suppression, immunological response and other risk factors among WLHA followed at an STD/HIV reference center. This was a cohort study conducted at a reference center for STD/AIDS in Northeastern Brazil from September 2013 to September 2015. Follow-up visits were conducted at 6 and 12 months after enrolment, where socio-epidemiological data were obtained. Cervical samples were collected for conventional cytology and HPV DNA research (PCR COBAS® Roche) in addition to blood samples for CD4+ T lymphocyte count and HIV viral load. We prospectively evaluated 333 women. HR-HPV DNA prevalence was 33.3% at baseline. HPV-16 was present in 5.1%, HPV-18 in 3.9% and 29.4% WLHA had other HR-HPV (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). The HR-HPV incidence during the follow-up was 10.8%, at the 6-month visit was 7.7% and at the 12-month visit was 3.7%. Variables associated with HR-HPV incidence were: nulliparity, combined oral contraceptive use and detectable HIV viral load. The HR-HPV clearance rate was 41.7% and was associated with age >30 years and lymphocyte T CD4 count >500 cells/mm3 at enrolment. These findings contribute to the knowledge about a group of women that need more careful HPV screening and describe the association between an efficient immunological response and HIV viral suppression with lower incidence and increased clearance of HR-HPV. |
doi_str_mv | 10.1371/journal.pone.0185423 |
format | article |
fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1991850936</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A508208850</galeid><doaj_id>oai_doaj_org_article_6e783953fdc14a8885e47135abbb558f</doaj_id><sourcerecordid>A508208850</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-cff31644605b333b75e297bb682fa53161be5b2b3946ced2af25ecb404e9e8573</originalsourceid><addsrcrecordid>eNqNkl1v0zAUhiMEYmPwDxBEQkJw0eLPxLlBGhPQSpM2AeutZTsnrafU7uyEr1-PQ7OpQbtAvvDXc97jc_xm2XOM5piW-N2174NT7XznHcwRFpwR-iA7xhUls4Ig-vBgfZQ9ifEaIU5FUTzOjoioBOYcH2dXlwFqazofYu6bfHG5yq0ztgZnIFeuzk0LKqhhZ12ucuM3PnQD-iGo37a1yuWL5WpmXQOmgzr_4bfgnmaPGtVGeDbOJ9nVp4_fzhaz84vPy7PT85kpKtLNTNNQXDBWIK4ppbrkQKpS60KQRvF0hTVwTTStWGGgJqohHIxmiEEFgpf0JHu51921PsqxI1Hiqkr9QBUtErHcE7VX13IX7FaFX9IrK_8e-LCWKnQ2VSkLKAWtOG1qg5kSQnBgJaZcaa05F03Sej9m6_UWagOuC6qdiE5vnN3Itf8ueUGEwMNz34wCwd_0EDu5tdFA2yoHvh_ezUTJKWM8oa_-Qe-vbqTWKhWQ_sCnvGYQlaccCYJSEShR83uoNGrYWpPs09h0Pgl4OwlITAc_u7XqY5TLr1_-n71YTdnXB-wGVNttom_7znoXpyDbgyb4GAM0d03GSA7uv-2GHNwvR_ensBeHH3QXdGt3-gd_Xv15</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1991850936</pqid></control><display><type>article</type><title>Predictors of HPV incidence and clearance in a cohort of Brazilian HIV-infected women</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Travassos, Ana Gabriela ; Netto, Eduardo ; Xavier-Souza, Eveline ; Nóbrega, Isabella ; Adami, Karina ; Timbó, Maiara ; Abbehusen, Karen ; Fernandes, Sheyla ; Duran, Camila ; Haguihara, Tatiana ; Ferreira, Fábio ; Brites, Carlos</creator><contributor>Barnabas, Ruanne V.</contributor><creatorcontrib>Travassos, Ana Gabriela ; Netto, Eduardo ; Xavier-Souza, Eveline ; Nóbrega, Isabella ; Adami, Karina ; Timbó, Maiara ; Abbehusen, Karen ; Fernandes, Sheyla ; Duran, Camila ; Haguihara, Tatiana ; Ferreira, Fábio ; Brites, Carlos ; Barnabas, Ruanne V.</creatorcontrib><description>Persistent infection with high-risk human papillomavirus (HR-HPV) is necessary for the development of precursor lesions and cervical cancer. HPV infection among women living with HIV/AIDS (WLHA) occurs more frequently, presents a higher rate of persistent infections and an earlier progression to cancer. We aimed to evaluate HR-HPV prevalence, incidence and clearance, and its association with HIV viral suppression, immunological response and other risk factors among WLHA followed at an STD/HIV reference center. This was a cohort study conducted at a reference center for STD/AIDS in Northeastern Brazil from September 2013 to September 2015. Follow-up visits were conducted at 6 and 12 months after enrolment, where socio-epidemiological data were obtained. Cervical samples were collected for conventional cytology and HPV DNA research (PCR COBAS® Roche) in addition to blood samples for CD4+ T lymphocyte count and HIV viral load. We prospectively evaluated 333 women. HR-HPV DNA prevalence was 33.3% at baseline. HPV-16 was present in 5.1%, HPV-18 in 3.9% and 29.4% WLHA had other HR-HPV (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). The HR-HPV incidence during the follow-up was 10.8%, at the 6-month visit was 7.7% and at the 12-month visit was 3.7%. Variables associated with HR-HPV incidence were: nulliparity, combined oral contraceptive use and detectable HIV viral load. The HR-HPV clearance rate was 41.7% and was associated with age >30 years and lymphocyte T CD4 count >500 cells/mm3 at enrolment. These findings contribute to the knowledge about a group of women that need more careful HPV screening and describe the association between an efficient immunological response and HIV viral suppression with lower incidence and increased clearance of HR-HPV.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0185423</identifier><identifier>PMID: 28981551</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Acquired immune deficiency syndrome ; Adult ; AIDS ; Alphapapillomavirus - physiology ; Analysis ; Antiretroviral drugs ; Biology and Life Sciences ; Brazil - epidemiology ; Cancer ; CD4 antigen ; Cell cycle ; Cell number ; Cervical cancer ; Cervix ; Chlamydia ; Cytology ; Deoxyribonucleic acid ; Development and progression ; DNA ; Epidemiology ; Female ; Gynecology ; Health aspects ; Health risks ; HIV ; HIV Infections - complications ; Human immunodeficiency virus ; Human papillomavirus ; Humans ; Immune response ; Immunology ; Incidence ; Infections ; Lesions ; Load distribution ; Lymphocytes T ; Medical diagnosis ; Medical screening ; Medicine and Health Sciences ; Oxidative stress ; Papillomavirus infections ; Papillomavirus Infections - complications ; Papillomavirus Infections - epidemiology ; Papillomavirus Infections - virology ; Persistent infection ; Prevalence ; Prospective Studies ; Risk analysis ; Risk factors ; Sexually transmitted diseases ; STD ; Studies ; Vaccines ; Women ; Womens health</subject><ispartof>PloS one, 2017-10, Vol.12 (10), p.e0185423-e0185423</ispartof><rights>COPYRIGHT 2017 Public Library of Science</rights><rights>2017 Travassos et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2017 Travassos et al 2017 Travassos et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-cff31644605b333b75e297bb682fa53161be5b2b3946ced2af25ecb404e9e8573</citedby><cites>FETCH-LOGICAL-c692t-cff31644605b333b75e297bb682fa53161be5b2b3946ced2af25ecb404e9e8573</cites><orcidid>0000-0001-9242-828X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1991850936/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1991850936?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768,74869</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28981551$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Barnabas, Ruanne V.</contributor><creatorcontrib>Travassos, Ana Gabriela</creatorcontrib><creatorcontrib>Netto, Eduardo</creatorcontrib><creatorcontrib>Xavier-Souza, Eveline</creatorcontrib><creatorcontrib>Nóbrega, Isabella</creatorcontrib><creatorcontrib>Adami, Karina</creatorcontrib><creatorcontrib>Timbó, Maiara</creatorcontrib><creatorcontrib>Abbehusen, Karen</creatorcontrib><creatorcontrib>Fernandes, Sheyla</creatorcontrib><creatorcontrib>Duran, Camila</creatorcontrib><creatorcontrib>Haguihara, Tatiana</creatorcontrib><creatorcontrib>Ferreira, Fábio</creatorcontrib><creatorcontrib>Brites, Carlos</creatorcontrib><title>Predictors of HPV incidence and clearance in a cohort of Brazilian HIV-infected women</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Persistent infection with high-risk human papillomavirus (HR-HPV) is necessary for the development of precursor lesions and cervical cancer. HPV infection among women living with HIV/AIDS (WLHA) occurs more frequently, presents a higher rate of persistent infections and an earlier progression to cancer. We aimed to evaluate HR-HPV prevalence, incidence and clearance, and its association with HIV viral suppression, immunological response and other risk factors among WLHA followed at an STD/HIV reference center. This was a cohort study conducted at a reference center for STD/AIDS in Northeastern Brazil from September 2013 to September 2015. Follow-up visits were conducted at 6 and 12 months after enrolment, where socio-epidemiological data were obtained. Cervical samples were collected for conventional cytology and HPV DNA research (PCR COBAS® Roche) in addition to blood samples for CD4+ T lymphocyte count and HIV viral load. We prospectively evaluated 333 women. HR-HPV DNA prevalence was 33.3% at baseline. HPV-16 was present in 5.1%, HPV-18 in 3.9% and 29.4% WLHA had other HR-HPV (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). The HR-HPV incidence during the follow-up was 10.8%, at the 6-month visit was 7.7% and at the 12-month visit was 3.7%. Variables associated with HR-HPV incidence were: nulliparity, combined oral contraceptive use and detectable HIV viral load. The HR-HPV clearance rate was 41.7% and was associated with age >30 years and lymphocyte T CD4 count >500 cells/mm3 at enrolment. These findings contribute to the knowledge about a group of women that need more careful HPV screening and describe the association between an efficient immunological response and HIV viral suppression with lower incidence and increased clearance of HR-HPV.</description><subject>Acquired immune deficiency syndrome</subject><subject>Adult</subject><subject>AIDS</subject><subject>Alphapapillomavirus - physiology</subject><subject>Analysis</subject><subject>Antiretroviral drugs</subject><subject>Biology and Life Sciences</subject><subject>Brazil - epidemiology</subject><subject>Cancer</subject><subject>CD4 antigen</subject><subject>Cell cycle</subject><subject>Cell number</subject><subject>Cervical cancer</subject><subject>Cervix</subject><subject>Chlamydia</subject><subject>Cytology</subject><subject>Deoxyribonucleic acid</subject><subject>Development and progression</subject><subject>DNA</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Gynecology</subject><subject>Health aspects</subject><subject>Health risks</subject><subject>HIV</subject><subject>HIV Infections - complications</subject><subject>Human immunodeficiency virus</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immunology</subject><subject>Incidence</subject><subject>Infections</subject><subject>Lesions</subject><subject>Load distribution</subject><subject>Lymphocytes T</subject><subject>Medical diagnosis</subject><subject>Medical screening</subject><subject>Medicine and Health Sciences</subject><subject>Oxidative stress</subject><subject>Papillomavirus infections</subject><subject>Papillomavirus Infections - complications</subject><subject>Papillomavirus Infections - epidemiology</subject><subject>Papillomavirus Infections - virology</subject><subject>Persistent infection</subject><subject>Prevalence</subject><subject>Prospective Studies</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Sexually transmitted diseases</subject><subject>STD</subject><subject>Studies</subject><subject>Vaccines</subject><subject>Women</subject><subject>Womens health</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNkl1v0zAUhiMEYmPwDxBEQkJw0eLPxLlBGhPQSpM2AeutZTsnrafU7uyEr1-PQ7OpQbtAvvDXc97jc_xm2XOM5piW-N2174NT7XznHcwRFpwR-iA7xhUls4Ig-vBgfZQ9ifEaIU5FUTzOjoioBOYcH2dXlwFqazofYu6bfHG5yq0ztgZnIFeuzk0LKqhhZ12ucuM3PnQD-iGo37a1yuWL5WpmXQOmgzr_4bfgnmaPGtVGeDbOJ9nVp4_fzhaz84vPy7PT85kpKtLNTNNQXDBWIK4ppbrkQKpS60KQRvF0hTVwTTStWGGgJqohHIxmiEEFgpf0JHu51921PsqxI1Hiqkr9QBUtErHcE7VX13IX7FaFX9IrK_8e-LCWKnQ2VSkLKAWtOG1qg5kSQnBgJaZcaa05F03Sej9m6_UWagOuC6qdiE5vnN3Itf8ueUGEwMNz34wCwd_0EDu5tdFA2yoHvh_ezUTJKWM8oa_-Qe-vbqTWKhWQ_sCnvGYQlaccCYJSEShR83uoNGrYWpPs09h0Pgl4OwlITAc_u7XqY5TLr1_-n71YTdnXB-wGVNttom_7znoXpyDbgyb4GAM0d03GSA7uv-2GHNwvR_ensBeHH3QXdGt3-gd_Xv15</recordid><startdate>20171005</startdate><enddate>20171005</enddate><creator>Travassos, Ana Gabriela</creator><creator>Netto, Eduardo</creator><creator>Xavier-Souza, Eveline</creator><creator>Nóbrega, Isabella</creator><creator>Adami, Karina</creator><creator>Timbó, Maiara</creator><creator>Abbehusen, Karen</creator><creator>Fernandes, Sheyla</creator><creator>Duran, Camila</creator><creator>Haguihara, Tatiana</creator><creator>Ferreira, Fábio</creator><creator>Brites, Carlos</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-9242-828X</orcidid></search><sort><creationdate>20171005</creationdate><title>Predictors of HPV incidence and clearance in a cohort of Brazilian HIV-infected women</title><author>Travassos, Ana Gabriela ; Netto, Eduardo ; Xavier-Souza, Eveline ; Nóbrega, Isabella ; Adami, Karina ; Timbó, Maiara ; Abbehusen, Karen ; Fernandes, Sheyla ; Duran, Camila ; Haguihara, Tatiana ; Ferreira, Fábio ; Brites, Carlos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-cff31644605b333b75e297bb682fa53161be5b2b3946ced2af25ecb404e9e8573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Adult</topic><topic>AIDS</topic><topic>Alphapapillomavirus - physiology</topic><topic>Analysis</topic><topic>Antiretroviral drugs</topic><topic>Biology and Life Sciences</topic><topic>Brazil - epidemiology</topic><topic>Cancer</topic><topic>CD4 antigen</topic><topic>Cell cycle</topic><topic>Cell number</topic><topic>Cervical cancer</topic><topic>Cervix</topic><topic>Chlamydia</topic><topic>Cytology</topic><topic>Deoxyribonucleic acid</topic><topic>Development and progression</topic><topic>DNA</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Gynecology</topic><topic>Health aspects</topic><topic>Health risks</topic><topic>HIV</topic><topic>HIV Infections - complications</topic><topic>Human immunodeficiency virus</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immunology</topic><topic>Incidence</topic><topic>Infections</topic><topic>Lesions</topic><topic>Load distribution</topic><topic>Lymphocytes T</topic><topic>Medical diagnosis</topic><topic>Medical screening</topic><topic>Medicine and Health Sciences</topic><topic>Oxidative stress</topic><topic>Papillomavirus infections</topic><topic>Papillomavirus Infections - complications</topic><topic>Papillomavirus Infections - epidemiology</topic><topic>Papillomavirus Infections - virology</topic><topic>Persistent infection</topic><topic>Prevalence</topic><topic>Prospective Studies</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Sexually transmitted diseases</topic><topic>STD</topic><topic>Studies</topic><topic>Vaccines</topic><topic>Women</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Travassos, Ana Gabriela</creatorcontrib><creatorcontrib>Netto, Eduardo</creatorcontrib><creatorcontrib>Xavier-Souza, Eveline</creatorcontrib><creatorcontrib>Nóbrega, Isabella</creatorcontrib><creatorcontrib>Adami, Karina</creatorcontrib><creatorcontrib>Timbó, Maiara</creatorcontrib><creatorcontrib>Abbehusen, Karen</creatorcontrib><creatorcontrib>Fernandes, Sheyla</creatorcontrib><creatorcontrib>Duran, Camila</creatorcontrib><creatorcontrib>Haguihara, Tatiana</creatorcontrib><creatorcontrib>Ferreira, Fábio</creatorcontrib><creatorcontrib>Brites, Carlos</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>Biological Sciences</collection><collection>Agriculture Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest advanced technologies & aerospace journals</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Travassos, Ana Gabriela</au><au>Netto, Eduardo</au><au>Xavier-Souza, Eveline</au><au>Nóbrega, Isabella</au><au>Adami, Karina</au><au>Timbó, Maiara</au><au>Abbehusen, Karen</au><au>Fernandes, Sheyla</au><au>Duran, Camila</au><au>Haguihara, Tatiana</au><au>Ferreira, Fábio</au><au>Brites, Carlos</au><au>Barnabas, Ruanne V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictors of HPV incidence and clearance in a cohort of Brazilian HIV-infected women</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2017-10-05</date><risdate>2017</risdate><volume>12</volume><issue>10</issue><spage>e0185423</spage><epage>e0185423</epage><pages>e0185423-e0185423</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Persistent infection with high-risk human papillomavirus (HR-HPV) is necessary for the development of precursor lesions and cervical cancer. HPV infection among women living with HIV/AIDS (WLHA) occurs more frequently, presents a higher rate of persistent infections and an earlier progression to cancer. We aimed to evaluate HR-HPV prevalence, incidence and clearance, and its association with HIV viral suppression, immunological response and other risk factors among WLHA followed at an STD/HIV reference center. This was a cohort study conducted at a reference center for STD/AIDS in Northeastern Brazil from September 2013 to September 2015. Follow-up visits were conducted at 6 and 12 months after enrolment, where socio-epidemiological data were obtained. Cervical samples were collected for conventional cytology and HPV DNA research (PCR COBAS® Roche) in addition to blood samples for CD4+ T lymphocyte count and HIV viral load. We prospectively evaluated 333 women. HR-HPV DNA prevalence was 33.3% at baseline. HPV-16 was present in 5.1%, HPV-18 in 3.9% and 29.4% WLHA had other HR-HPV (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). The HR-HPV incidence during the follow-up was 10.8%, at the 6-month visit was 7.7% and at the 12-month visit was 3.7%. Variables associated with HR-HPV incidence were: nulliparity, combined oral contraceptive use and detectable HIV viral load. The HR-HPV clearance rate was 41.7% and was associated with age >30 years and lymphocyte T CD4 count >500 cells/mm3 at enrolment. These findings contribute to the knowledge about a group of women that need more careful HPV screening and describe the association between an efficient immunological response and HIV viral suppression with lower incidence and increased clearance of HR-HPV.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>28981551</pmid><doi>10.1371/journal.pone.0185423</doi><tpages>e0185423</tpages><orcidid>https://orcid.org/0000-0001-9242-828X</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1932-6203 |
ispartof | PloS one, 2017-10, Vol.12 (10), p.e0185423-e0185423 |
issn | 1932-6203 1932-6203 |
language | eng |
recordid | cdi_plos_journals_1991850936 |
source | Publicly Available Content Database; PubMed Central |
subjects | Acquired immune deficiency syndrome Adult AIDS Alphapapillomavirus - physiology Analysis Antiretroviral drugs Biology and Life Sciences Brazil - epidemiology Cancer CD4 antigen Cell cycle Cell number Cervical cancer Cervix Chlamydia Cytology Deoxyribonucleic acid Development and progression DNA Epidemiology Female Gynecology Health aspects Health risks HIV HIV Infections - complications Human immunodeficiency virus Human papillomavirus Humans Immune response Immunology Incidence Infections Lesions Load distribution Lymphocytes T Medical diagnosis Medical screening Medicine and Health Sciences Oxidative stress Papillomavirus infections Papillomavirus Infections - complications Papillomavirus Infections - epidemiology Papillomavirus Infections - virology Persistent infection Prevalence Prospective Studies Risk analysis Risk factors Sexually transmitted diseases STD Studies Vaccines Women Womens health |
title | Predictors of HPV incidence and clearance in a cohort of Brazilian HIV-infected women |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T09%3A11%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictors%20of%20HPV%20incidence%20and%20clearance%20in%20a%20cohort%20of%20Brazilian%20HIV-infected%20women&rft.jtitle=PloS%20one&rft.au=Travassos,%20Ana%20Gabriela&rft.date=2017-10-05&rft.volume=12&rft.issue=10&rft.spage=e0185423&rft.epage=e0185423&rft.pages=e0185423-e0185423&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0185423&rft_dat=%3Cgale_plos_%3EA508208850%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c692t-cff31644605b333b75e297bb682fa53161be5b2b3946ced2af25ecb404e9e8573%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1991850936&rft_id=info:pmid/28981551&rft_galeid=A508208850&rfr_iscdi=true |